Sodium valproate and sumatriptan in acute migraine attack

Comparisson the effect of sodium valproate and sumatriptan on acute migraine attack

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108025943N4

Enrollment

Registered

2011-10-27

Start date

2011-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migrane.

Interventions

Intervention 1: Sodium valproate, 400 mg, stat, intravenously. Intervention 2: Sumatriptan, 6 mg, stat, subcutaneously.

Treatment - Drugs

Sodium valproate, 400 mg, stat, intravenously

Sumatriptan, 6 mg, stat, subcutaneously

Eligibility

Sex/Gender

All

Age

15 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: presence of acute migraine attack, age between 15 to 50 years old Exclusion criteria: pregnancy, liver disease, ischemic heart disease, hypertension, receiving ergotamine during past hours prior to the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Headache Severity. Timepoint: Mean headache severity of patients,pretreatment,half,one and 2 hours after treatment will be measured. Method of measurement: Based on pain measurement ciriterion,Verbal numerical rating scale ,(from 0 to 10).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Mellat Ardekani

Yazd University of Medical Sciences

ali_mellat@ssu.ac.ir+98 35 1822 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026